Shares of Sun Pharmaceutical Industries Ltd jumped more than 5% in early trade after the company announced a major global acquisition deal involving Organon & Co. The transaction marks one of the largest overseas acquisitions by an Indian pharmaceutical company in recent years. As of 9:22 AM, the shares were trading 5.23% higher at Rs 1,705.10.
Deal Overview
Sun Pharma has entered into a definitive agreement to acquire all outstanding shares of Organon at a price of $14.00 per share in an all-cash transaction. The deal carries an enterprise valuation of approximately $11.75 billion. It has already received approval from the boards of both companies and now awaits regulatory clearances and shareholder approval from Organon.
About Organon
Organon was formed in 2021 as a spin-off from Merck & Co.. The company has built a strong global presence, particularly in women’s health, and operates a diversified portfolio of over 70 products. Its business spans across 140 countries, with key markets including the United States, Europe, China, Canada, and Brazil. Organon also operates six manufacturing facilities across the European Union and emerging markets.
Strategic Rationale
The acquisition aligns with Sun Pharma’s long-term strategy to expand its innovative medicines portfolio while strengthening its presence in branded generics and established medicines. The deal will also enable the company to enter the biosimilars segment as a top-10 global player.
With Organon’s portfolio and global footprint, Sun Pharma is expected to enhance its scale, diversify revenue streams, and strengthen its relationships with healthcare providers and regulators worldwide.
Combined Business Strength
Following the completion of the transaction, the combined entity is expected to:
- Become one of the top 25 global pharmaceutical companies with combined revenues of $12.4 billion
- Strengthen its position in the established brands and branded generics segment
- Increase focus on innovative medicines, contributing around 27% to total revenue
- Emerge as a top 3 global player in women’s health
- Rank as the 7th largest biosimilar company globally
- Expand its presence to 150 countries with strong market depth
- Nearly double EBITDA and cash flows, supporting deleveraging with a projected Net Debt/EBITDA ratio of 2.3x
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.